2018 Precision Cancer Medicine Symposium | Center for Precision Cancer Medicine

Over the past decade, there have been major advancements in the field of precision medicine, leading to exciting new treatments for some cancer patients. Much attention has been focused on genomic profiling of tumors to identify genomic alterations that might guide selection of specific therapies for individual patients. Beyond genomics, however, there is a variety of other precision approaches that can identify and exploit cancer-specific biological mechanisms including proteomics, metabolomics, and computational modeling, resulting in the more effective use of existing cancer medicines. On Thursday, December 13, 2018, the MIT Center for Precision Cancer Medicine will hold its inaugural annual symposium in the Samberg Conference Center at MIT. This full-day event will feature leading researchers and clinicians, who will highlight recent advances in precision cancer medicine and share perspectives on the future. An industry panel will also discuss the barriers to instituting precision medicine into current and future clinical trials.

View Agenda

For sponsorship opportunities and additional information, please contact Leny Gocheva.

Keynote Address

Lineage Plasticity in Prostate Cancer

Charles Sawyers, MD

Chair, Human Oncology and Pathogenesis Program
Memorial Sloan Kettering Cancer Center

Speakers

	A Mechanistic Framework for the Systematic Pharmacological Targeting of Non-Oncogene Dependencies: Towards a More “Precise” Implementation of Precision Oncology Andrea Califano, PhD Clyde and Helen Wu Professor of Chemical Systems Biology, Columbia University Chair, Department of Systems Biology, Columbia University Director, JP Sulzberger Columbia Genome Center Associate Director, Herbert Irving Comprehensive Cancer Center
	Advancing Technologies for Discovery and Production in Precision Medicine J. Christopher Love, PhD Professor of Chemical Engineering, MIT Associate Member, Ragon Institute of MGH, MIT and Harvard Member, Koch Institute, MIT
	Precision Medicine in Melanoma: Are We There Yet? Richard Marais, PhD Professor of Molecular Oncology Director, CRUK Manchester Institute  The University of Manchester
	Precision Cancer Medicine: Neither Silver Bullet Nor an Illusion Kenna Mills Shaw, PhD Executive Director Sheikh Khalifa Bin Zayed al Nahyan Institute for Personalized Cancer Therapy MD Anderson Cancer Center
	Evolution of Drug Resistance in Oncogene-Driven Lung Cancer Alice Shaw, MD, PhD Professor, Harvard Medical School Director, Thoracic Cancer Program, Massachusetts General Hospital
	Targeting Metabolism in Cancer Matthew Vander Heiden, MD, PhD Associate Professor of Biology, MIT Associate Director, Koch Institute Member, MIT Center for Precision Cancer Medicine
	Using Systems Biology of DNA-damage Signaling to Improve Cancer Treatment Michael B. Yaffe, MD, PhD David H. Koch Professor of Science, MIT Professor of Biology and Biological Engineering, MIT Director, MIT Center for Precision Cancer Medicine Director, Koch Institute Clinical Investigator Program Member, Koch Institute, MIT
	Integrating Immunotherapy and Targeted Therapies in Cancer Treatment: From Mouse Models to Human Therapies Jean Zhao, PhD Professor of Biological Chemistry and Molecular Pharmacology Harvard Medical School and Dana-Farber Cancer Institute

Panelists: Barriers to Instituting Precision Medicine in Clinical Trials

	Peter Hammerman, MD, PhD Global Head, Translational Research Oncology Disease Area Novartis Institutes for BioMedical Research
	Steffan N. Ho, MD, PhD Vice President, Head of Translational Oncology Pfizer Global Product Development
	Shiva Malek, PhD Director and Principal Scientist Department of Discovery Oncology Genentech Inc
	Kevin Marks, PhD VP of Biology Agios Pharmaceuticals
	S. Michael Rothenberg, MD, PhD Vice-President, Research and Development Loxo Oncology, Inc.
	Moderator Angela Koehler, PhD Goldblith Career Development Professor in Applied Biology, MIT Member, Koch Institute for Integrative Cancer Research Member, MIT Center for Precision Cancer Medicine